Assessing Genomic Testing’s Impact on Prostate Cancer (Video)

Genomic testing is increasingly impacting prostate cancer diagnosis and treatment, helping clinicians make more informed management decisions based on the specific molecular characteristics of an individual patient’s cancer. In a video interview, Eric A. Klein, MD, Chairman of Cleveland Clinic’s Glickman Urological & Kidney Institute, discusses the broadening use of molecular-based tests.

Androgen-Enhancing Gene Mutation Reduces Prostate Cancer Survival

Prostate cancer patients with an inherited gene mutation that enables intratumoral androgen synthesis are highly likely to develop resistance to androgen deprivation therapy and to die years earlier of their disease, researchers from Cleveland Clinic and Mayo Clinic have found. A screening test based on the mutation could inform clinical care.

Novel Androgen Receptor-Targeting Therapies May Overcome Castration Resistance in Aggressive Prostate Cancer

Androgen deprivation therapy, which prevents androgen receptor signaling, initially is effective against advanced prostate cancer but progression eventually resumes, relying on androgen receptor’s transcriptional activity. Cleveland Clinic researchers are exploring new approaches that block this transactivation function, which may prevent or overcome resistance.